Velocardiofacial syndrome (VCFS) and DiGeorge syndrome (DGS) are characterized by a wide spectrum of abnormalities, including conotruncal heart defects, velopharyngeal insufficiency, craniofacial anomalies and learning disabilities. In addition, numerous other clinical features have been described, including frequent psychiatric illness. Hemizygosity for a 1.5-3 Mb region of chromosome 22q11 has been detected in >80% of VCFS/DGS patients. It is thought that a developmental field defect is responsible for many of the abnormalities seen in these patients and that the defect occurs due to reduced levels of a gene product active in early embryonic development. Goosecoid-like (GSCL) is a homeobox gene which is present in the VCFS/DGS commonly deleted region. The mouse homolog, Gscl, is expressed in mouse embryos as early as E8.5. Gscl is related to Goosecoid (Gsc), a gene required for proper craniofacial development in mice. GSCL has been considered an excellent candidate for contributing to the developmental defects in VCFS/DGS patients. To investigate the role of Goosecoid-like in VCFS/DGS etiology, we disrupted the Gscl gene in mouse embryonic stem cells and produced mice that transmit the disrupted allele. Mice that are homozygous for the disrupted allele appear to be normal and they do not exhibit any of the anatomical abnormalities seen in VCFS/DGS patients. RNA in situ hybridization to mouse embryo sections revealed that Gscl is expressed at E8.5 in the rostral region of the foregut and at E11.5 and E12.5 in the developing brain, in the pons region and in the choroid plexus of the fourth ventricle. Although the gene inactivation experiments indicate that haploinsufficiency for GSCL is unlikely to be the sole cause of the developmental field defect thought to be responsible for many of the abnormalities in VCFS/DGS patients, its localized expression during development could suggest that hemizygosity for GSCL, in combination with hemizygosity for other genes in 22q11, contributes to some of the developmental defects as well as the behavioral anomalies seen in these patients. The mice generated in this study should help in evaluating these possibilities.
INTRODUCTION
Interstitial deletions within human chromosome 22q11 are associated with two related autosomal dominant genetic disorders, velocardiofacial syndrome (VCFS; MIM 19263) and DiGeorge syndrome (DGS; MIM 188400) (1, 2) . The two syndromes are quite common, with a prevalence estimated to be 1 in 4000 live births (3) . The typical phenotypic features of VCFS include cleft palate, velopharyngeal insufficiency resulting in hypernasal speech, conotruncal cardiac anomalies, a characteristic facial dysmorphology and learning disabilities (4, 5) . The penetrance and severity of each anomaly vary significantly among VCFS patients and numerous additional anomalies have also been described, including skeletal muscle hypotonia, thrombocytopenia, mental retardation and psychiatric illness (6) (7) (8) . DGS patients share many of the features seen in VCFS patients, including hypocalcemia due to hypoparathyroidism and immune deficiencies due to congenital hypoplasia or aplasia of the thymus (5) .
Most of VCFS/DGS patients have similar, large hemizygous deletions in 22q11 (9) (10) (11) (12) . Some patients have unique 22q11 deletions or translocations and the description of such patients has led to various hypotheses concerning the definition of a critical region in which the gene or genes responsible for these *To whom correspondence should be addressed. Tel: +1 718 430 2169; Fax: +1 718 430 8574; Email: skoultch@aecom.yu.edu syndromes is expected to reside (13, 14) . However, there is no consensus regarding the definition of the critical region and attempts to narrowly define such a region based on the positions of chromosomal rearrangements are suspect because of the possibility that genomic rearrangements may exert position effects on expression of distant genes (15) (16) (17) (18) . At least 18 genes and several ESTs have been identified within the VCFS/DGS commonly deleted region, but to date no mutations in these genes have been reported in patients that lack any detectable deletion or rearrangement in 22q11. An alternative approach to identifying patients with mutations in a specific gene(s) is to evaluate the possible contribution of genes in 22q11 to the syndromes by analyzing animals in which expression of a candidate gene has been inactivated. The development of methods for introducing gene-specific inactivating mutations into the germline of mice provides such an opportunity.
A substantial body of evidence points to a defect in early embryonic development as the cause of many of the abnormalities present in VCFS/DGS patients. Several of the tissues and organ systems that are affected in these syndromes are derived from the pharyngeal arches and pouches. During early development these structures are populated by migrating cephalic neural crest cells. The importance of cephalic neural crest-derived cells in the development of the conotruncal region of the heart, the thymus and parathyroid glands and the connective tissues of the lower face and neck, all structures that are affected in VCFS/ DGS, has been demonstrated by microablation and transplantation studies in avian embryos (reviewed in refs [19] [20] [21] . Based on these observations it is reasonable to hypothesize that a gene or genes located within the 22q11 commonly deleted region is involved in the processes of neural crest cell migration or differentiation in the pharyngeal arches and that haploinsufficiency of such a gene(s) disrupts proper development of these systems leading to multiple organ and tissue abnormalities. Therefore, an important criterion for the involvement of a candidate gene in VCFS/DGS etiology is that it be expressed in the developing embryo when these processes occur. Alternatively, or in addition, haploinsufficiency of individual genes may contribute to specific aspects of the VCFS/DGS phenotype by causing a reduction in the amount of gene products required for proper organogenesis of specific tissues at later stages of development.
Homeodomain-containing proteins represent a very large family of transcription factors that play key roles in many developmental processes (22) (23) (24) (25) . Studies of mice in which specific members of this family have been inactivated indicate that several of them are involved in developmental processes relevant to VCFS/DGS etiology (26) (27) (28) (29) . However, the human orthologs of these genes are not located within human chromosome 22q11. Our group and others recently described a gene, Goosecoid-like (GSCL), lying in 22q11, that is capable of encoding a homeodomain-containing protein (30, 31) . GSCL is related to a previously described homeobox gene, Goosecoid (GSC) (32) , in both genomic organization and the sequence of the homeodomain. Gsc is expressed in developing mouse embryos (33, 34) and gene inactivation experiments show that it is required for proper craniofacial and rib cage development (27, 28, 35) . We found that Gscl is also expressed in early mouse embryos, from E8.5 to 10.5, the time of neural crest migration and differentiation in the pharyngeal arches, as well as a later times during organogenesis (30) . Thus, Gscl would appear to be an excellent candidate for contributing to VCFS/DGS etiology. To investigate this possibility we disrupted the Gscl gene in mouse embryonic stem cells and produced mice homozygous for the disrupted allele. These mice are viable and do not exhibit any of the major anatomical abnormalities seen in VCFS/DGS patients. Nevertheless, the sites of Gscl expression during mouse embryogenesis suggest that hemizygosity for GSCL, in combination with hemizygosity for other genes in 22q11, could contribute to some aspects of the VCFS/DGS phenotype.
RESULTS

Generation of ES cells with a disrupted Gscl gene
The mouse Gscl gene contains an open reading frame of 618 bp encompassed in three exons that span 1293 bp of genomic DNA sequence (36) . To disrupt the Gscl gene a targeting vector (Fig.  1) was constructed in which a 2.3 kb segment including the complete open reading frame, 840 bp of the putative promoter region and 100 bp 3′ of the termination codon (36) was deleted and replaced by a cassette containing a gene that confers resistance to hygromycin. The cassette also included two other features that are useful for future genomic manipulations: a LoxP site and a promoterless gene that can confer resistance to puromycin. The linearized targeting vector was electroporated into WW6 ES cells (37) and cells resistant to hygromycin were selected. Genomic DNA from 384 hygromycin-resistant clones were pooled (6 colonies/pool) and tested for gene targeting events by long-range PCR utilizing a primer lying outside the targeting construct (Gscl K03, Fig. 1 ) and a primer lying in the hygromycin resistance gene (Hyg-K01, Fig. 1 ). Twenty one pools gave the expected 5.6 kb PCR product and upon subsequent analysis a total of 31 colonies exhibited the 5.6 kb product (Fig. 2) . The results correspond to an overall targeting frequency of 8.1% among the hygromycin-resistant clones.
Production of Gscl null mice
Several ES cell clones (Fig. 2) containing the modified Gscl locus were injected into C57BL/6 blastocysts to generate chimeric mice. Two cell lines generated chimeras ranging in chimerism between 50 and 90% as judged by coat color. Male chimeras were mated with C57BL/6 females. PCR analysis of tail DNA from offspring carrying the dominant, ES cell-derived agouti coat color marker showed that the chimeras could transmit the modified Gscl allele (data not shown). To determine whether Gscl is necessary for mouse development, mice heterozygous for the modified Gscl allele were interbred. Examples of Southern blot analyses of tail DNA from the progeny (Fig. 3A) indicate that animals homozygous for the modified Gscl allele are viable. Of 239 animals examined in this way, 64 (26.8%) carried only the wild-type allele, 121 (50.6%) carried one copy of the modified allele and 54 (22.6%) carried two copies of the modified allele. The ratio of the three classes of animals is not significantly different from the expected values for Mendelian transmission of the two alleles.
To show that the Gscl gene is indeed a single copy gene, Southern blots of tail DNA were probed with a segment of Gscl exon 1 that was deleted in the targeting vector. No hybridizing bands were observed in DNA samples from mice homozygous for the modified allele (Fig. 3B) . Since the modified Gscl locus is expected to be deleted of the three Gscl exons as well as portions of the 5′ and 3′ regions and since the Southern blotting experiments showed that no rearrangements had occurred that resulted in an intact Gscl gene, Gscl transcripts are expected to be completely absent in mice homozygous for the modified allele. Gscl transcripts are detectable during embryogenesis and in the testis of adult mice (30) as well as in newborn and adult mouse brain (Fig. 4) . Total RNA from testes and brains of Gscl +/+, +/-and -/-animals was assayed for Gscl transcripts by RT-PCR using primers lying in exons 2 and 3. The expected 122 bp product was produced from the RNA of Gscl +/+ and +/-mice, but it was completely absent in reactions containing cDNA from Gscl -/-animals ( Fig. 4) . Generation of the 122 bp product in samples from animals containing at least one wild-type allele was completely dependent on the presence of reverse transcriptase (Fig. 4) . As an internal control for production of cDNA by oligo(dT) priming and reverse transcription, all cDNA preparations were subjected to PCR with primers specific for the ubiquitously expressed Sez12 gene. The expected 550 bp product was generated in all samples. We conclude that the modification introduced into the Gscl gene by homologous recombination indeed resulted in a null mutation.
Expression pattern of Gscl in mouse embryos
We reported previously that Gscl transcripts were detectable by RT-PCR in mouse embryos from E8.5 to 13.5 (30) . The absence of such transcripts in northern blot analyses suggested very low level expression or possibly a highly localized expression pattern. To investigate the sites of Gscl expression during embryogenesis we carried out RNA in situ hybridization experiments to serial transverse and sagittal sections of mouse embryos from E8.5 to Reactions in (C) were performed with primers specific for the mouse IDD (Sez12) gene as described previously (30) . (D-F) Reactions with brain RNA samples. T +/+, testis RNA from a Gscl +/+ animal; NB +/+, newborn brain RNA from a Gscl +/+ animal. Reactions in (E) and (F) were performed as described for (B) and (C), respectively. E12.5. Experiments were performed using antisense and sense probes corresponding to exon 3 and 460 bp of the putative 3′-untranslated region of Gscl. At E8.5, Gscl transcripts were detected in the endoderm of the ventral face of the rostral region of the foregut (Fig. 5B and C) . Here Gscl expression is present in a region close to the first pharyngeal arch artery (Fig. 5B) . By E11.5 Gscl-expressing cells become detectable at three sites in the developing brain. Relatively high expression was observed in the developing pons in a region containing the raphe nuclei, a system of serotonergic neurons (Fig. 6B) . At this stage, Gscl expression was also detected in the choroid plexus of the fourth ventricle (Fig. 6C) as well as in the dorsal part of the neuroepithelium of the third ventricle, in a very specific region localized dorsal of the habenula (Fig. 6D ). These sites of Gscl expression were also seen at E12.5 (data not shown). Because many of the abnormalities present in VCFS/DGS patients are thought to be due to a defect occurring in the pharyngeal arches, we examined these structures at various stages for Gscl expression. However, we failed to detect Gscl transcripts at any time in these regions.
Characterization of Gscl-deficient mice
Although the highly localized expression pattern of Gscl in embryos suggested that the gene may contribute to only a limited number of developmental processes, the in situ hybridization experiments cannot exclude low level expression at other sites. Therefore it was important to examine Gscl-deficient mice for any abnormal features. Gscl -/-mice exhibited normal birth weight and size and were indistinguishable from heterozygous and wild-type littermates. On necropsy, the sizes and weights of Gscl -/-mice were found to be within the normal range. To further characterize Gscl -/-mice, hematoxylin/eosin stained paraffin-embedded sections from 33 different tissues (see Materials and Methods) of 3-month-old mutant and control littermates were examined for pathological or abnormal histological features. No consistent differences between wildtype and homozygous mutant mice were detected. Since conotruncal heart defects are present in a high proportion of VCFS/DGS patients, special attention was given to analysis of the heart and the outflow tract. No abnormalities were detected either after examination of the heart and the conotruncal region during necropsy or when looking at the histological sections of the conotruncal region. These results indicate that the presence of the modified Gscl gene did not apparently impair normal development of the systems examined.
The RNA in situ hybridization experiments indicated highly localized expression of Gscl at several sites in the developing mouse brain. Therefore a detailed histological analysis of the central nervous system was performed on 1.5-to 3-month-old Gscl -/-mice and control littermates. The brain, spinal cord and optic chiasm were removed and coronal slices taken from the frontal, parietal and occipital levels of the cerebral hemispheres, from the cerebellum at the superior cerebellar peduncles and immediately caudal to the peduncles and from the spinal cord at the cervical, thoracic and lumbar levels. Ten micrometer paraffinembedded sections were stained with hematoxylin/eosin for general cytoarchitecture, Luxol fast blue for myelin and by the Bodian technique for axons and examined by light microscopy (38) . No consistent abnormalities were detected.
We reported previously that Gscl transcripts are detectable in adult mouse testis by RT-PCR (30) and a recent report indicates that Gscl is expressed in developing germ cells in embryonic gonadal tissue (39) . Therefore, we examined testis development and spermatogenesis in adult Gscl -/-mice. Both the testis weights and the appearance of hematoxylin/eosin stained paraffin-embedded sections of the testes of Gscl -/-males were normal. Gscl -/-male and female animals were interbred. These matings produced litters of normal size and the progeny appeared normal. However, male rodents can produce normal sized litters even if they have a reduced number of mature sperm (40) . Therefore, we also determined the number of epididymal sperm. Three 9-week-old Gscl -/-and wild-type male littermates were compared. The mature sperm number per animal was not different between homozygous mutants (2.5 ± 1.4 × 10 7 ) and wild-type (2.6 ± 1.2 × 10 7 ) males. These results indicate that the presence of the modified Gscl gene did not impair reproductive capacity nor production of mature sperm.
DISCUSSION
This report represents an attempt to investigate the etiology of an important multi-anomaly syndrome by inactivating the mouse ortholog of one of the genes in the VCFS/DGS commonly deleted region in chromosome 22q11. Gscl has been considered an excellent candidate for contributing to the developmental anomalies present in VCFS/DGS patients for several reasons. GSCL transcripts can be detected in 9-to 10-week human fetal tissue samples (30) . More extensive analysis at various stages of embryogenesis in mice showed that the gene is expressed both during early development and at later times during organogenesis (30, 41) . Events that occur during both periods are relevant to the specific defects seen in VCFS/DGS patients. Furthermore, Gscl is highly related in its homeodomain to Gsc (30, 36) , which gene inactivation experiments have shown is required for proper craniofacial development (27, 28, 35) . Despite this considerable circumstantial evidence pointing to a role for Gscl in VCFS/DGS etiology, the experiments reported here indicate that the gene is unlikely to be solely responsible for the developmental field defect thought to cause many of the anomalies seen in the patients. Gscl null mice are viable, they grow normally and are fertile and they exhibit no detectable anatomical or histological abnormalities. The analysis included examination of 33 different tissues from 30-month-old Gscl -/-animals for pathological or abnormal histological features, as well as extensive histology of the central nervous system using three types of stains. Although no abnormalities were found in these mice, as discussed below, it is still quite possible that Gscl plays a role in one or more aspects of the syndromes.
Most VCFS/DGS patients have similar, large hemizygous deletions encompassing numerous genes. Although attempts to define a critical region through analysis of unique patients with other deletions or chromosomal rearrangements have not led to a consensus, all of the regions proposed contain multiple genes. Many of these genes have been isolated but to date there is no definitive evidence implicating any one of them in the etiology of the syndrome. The fact that such a large proportion of patients have extensive deletions could suggest that haploinsufficiency of more than one gene from the 22q11 region is responsible for development of the VCFS/DGS phenotype. There is ample precedent for dosage-sensitive genetic interactions between developmental control genes, including observations of functional synergism between a close relative of Gscl, Goosecoid (Gsc), and other genes. For example, compound mutants between Gsc and Hepatic Nuclear Factor-3β (HNF3β) of the genotype Gsc -/-; Hnf3B +/-exhibit developmental defects not seen in single gene mutants, either Gsc -/-or Hnf3β +/-mice (42) . These defects occur in regions of the embryo where the two genes are co-expressed. Similarly, whereas Gsc -/-mice are born with normal limbs, Gsc/Mhox double mutant mice exhibit severe limb abnormalities (42, 43) . Thus, despite the absence of detectable abnormalities in Gscl -/-mice, GSCL still might play a role, in combination with hemizygosity of other genes in 22q11, in the developmental defects seen in VCFS/DGS patients. Our observation that Gscl is expressed in the rostral region of the developing foregut at E8.5 is particularly interesting, as this region gives rise to the embryonic pharynx and in turn portions of the adult nasal and oral cavities and larynx. Additional RNA in situ hybridization experiments are needed to evaluate the fate of Gscl-expressing cells in the foregut region of the embryo. Nevertheless, the observed expression of Gscl in this region of the foregut could suggest that hemizygosity of Gscl, along with another gene in 22q11, is involved in the velopharyngeal insufficiency seen frequently in VCFS/DGS patients. As mice bearing inactivating mutations in other genes from the VCFS/DGS region become available it will be possible to investigate combinatorial contributions of Gscl and the other genes to the VCFS/DGS phenotype by generating double mutant mice. Genes of particular interest in this context may be Hira and Tbx1, both of which, like Gscl, are expressed during embryogenesis and are presumptive nuclear proteins that affect transcriptional processes (44) (45) (46) .
In addition to the possibility that hemizygosity of Gscl along with another gene(s) contributes to the developmental defect in VCFS/DGS, it is also possible that Gscl deficiency, either alone or in combination with another deficiency, is responsible for the learning disabilities and/or behavioral anomalies seen frequently in VCFS/DGS patients. In recent years it has become apparent that these patients frequently have psychiatric illnesses. The most common psychiatric diagnoses in adult patients are schizophrenia, schizoaffective disorder and bipolar spectrum disorders. Adolescent patients exhibit attention deficit disorder as well as mood disorders. RNA in situ hybridization experiments showed that Gscl transcripts are present in a highly localized pattern in three regions of the developing mouse brain at E11.5 and 12.5. Consistent with recently reported work by other investigators (39,47), we found Gscl transcripts in a subregion of the developing pons. In addition, we found expression of Gscl RNA at these times in the choroid plexus of the fourth ventricle as well as in the neuroepithelium of the third ventricle dorsal of the habenula, which defines the boundary of the forebrain and midbrain regions. It is difficult to speculate at this time about the significance of these observations for the learning disabilities and behavioral problems present in the patients. The highly specific pattern of expression in the developing pons may be most significant, as this region contains the raphe nuclei, serotonincontaining neurons that have been implicated in control of behavior. It should also be noted that we detected expression of Gscl in newborn and adult mouse brain RNA by RT-PCR (Fig.  4) . In situ hybridization to sections of these tissues should prove to be informative for future investigations of Gscl -/-mice. Despite these intriguing observations, the detailed histological analysis of the entire central nervous system of adult Gscl -/-mice failed to reveal any abnormalities. Perhaps, as suggested above, deficiencies in the expression of more than one gene are involved in the etiology of the behavioral abnormalities in VCFS/DGS patients. Interestingly, another gene of unknown function, called ES2, lying adjacent to Gscl in the commonly deleted region, is co-expressed with Gscl in the pons in E14.5 mouse embryos (47) . Furthermore, it has been suggested that reduced levels of catechol O-methyltransferase (COMT), which is encoded by another gene in the commonly deleted region, may be involved in the mood disorders seen in VCFS/DGS patients (48) . A variety of experimental paradigms are available for testing the learning capacities and behavioral responses of rodents, including tests that are thought to be relevant to some of the behavioral anomalies present in VCFS/DGS patients. The mice produced in this study should be useful for evaluating the possibility that Gscl is involved in these aspects of the VCFS/ DGS phenotype.
Whether or not Gscl is involved in the etiology of VCFS/DGS, the mice and ES cells described here that contain a targeted insertion of a LoxP site at the Gscl locus should prove invaluable for ascertaining the role of other genes in the VCFS/DGS commonly deleted region in the syndromes. The strategy for accomplishing this goal is to incorporate LoxP sites at various locations proximal and distal of Gscl. Then, by bringing two LoxP sites together, either by animal breeding or by sequential ES cell transfections, it is possible to induce specific deletions encompassing different sets of genes by Cre-mediated recombination (49) . The reagents generated during the course of the current work represent the first step towards such genetic manipulations.
MATERIALS AND METHODS
Disruption of the Gscl gene in ES cells and generation of chimeric mice
Clone WW6 ES cells were cultured according to Ioffe (37) . NotI-linearized targeting vector (20 µg) was electroporated into 7 × 10 7 ES cells. ES cell colonies resistant to 150 µg/ml hygromycin (Boehringer Mannheim) were isolated and expanded. About 1 µg DNA prepared from pooled ES cells (6 colonies/pool) was analyzed using the Expand long template PCR kit (Boehringer Mannheim) using primers Gscl-KO3 (5′-ggggcagggtcagatacatgacga-3′) and Hyg-KO1 (5′-tactcgccgatagtggaaaccgac-3′) (Fig. 1) . PCR amplification cycles were as follows: 92_C for 10 s, 65_C for 30 s, 68_C for 3 min for 10 cycles followed by 25 cycles using the same conditions with addition of 10 s to each elongation step. PCR products were electrophoresed in an agarose gel and transferred to a Hybond N membrane (Amersham). The specificity of the 5.6 kb PCR product (Fig. 2) was assessed by hybridization with 20 ng internal primer Gscl-601 (5′-atggatgagtggtggccaca-3′) (Fig. 1) that was radiolabeled by a 3′-kinase reaction (New England Biolabs) as described by Hazan et al. (50) . ES cell clones were injected into C57BL/6 recipient blastocysts which were transferred to CD-1 pseudopregnant females (51) . Two ES cell clones (A16 and 1A5) produced chimeras which were used for breeding and analysis. For mouse genotyping, PCR reactions were set up to screen for the wild-type allele and the modified allele using primers Gscl-E (5′-agctggttggtagtgcct-3′) and Gscl-F (5′-aggagagttgttgatgctg-3′) and primers Gscl-E and Hyg-KO1, respectively. For Southern blot hybridization (52) , ES cell and mouse tail DNAs were prepared as described (53) . The 5′ probe (Fig. 1) used to detect wild-type and recombinant alleles was generated by PCR using primers Gscl-KOA (5′-agcttccccagggattctg-3′) and Gscl-KOBr (5′-cagcagcaggtaggactgga-3′).
Reverse transcriptase-mediated polymerase chain reaction
Total mouse tissue RNA was isolated using Trizol reagent (Gibco) following the manufacturer's instructions and northern blot hybridization was performed as described (52) . After DNase RQ1 (Promega) treatment, 5 µg of total RNA were reverse transcribed with oligo(dT) primers using the SuperScript II kit (Gibco BRL) following the manufacturer's instructions. PCR was performed on one tenth volume of the reverse transcription reaction using primers Gscl-R (5′-gagaggagcgcgtggag-3′) and Gscl-3 (5′-gcatcaacaactctccttgg-3′) with an annealing temperature of 56_C. The specificity of the 122 bp product was checked by hybridization with primer Gscl-T (5′-cttttggtgtcgccactttgcc-3′) as described above. The cDNA integrity was checked by PCR amplification with primer specific for the ubiquitously expressed Sez12 gene as described (30) .
Histological analysis of mouse tissues
For analysis of central nervous system tissues, mice were anesthetized and perfused via the left cardiac ventricle with 20 ml cold phosphate-buffered 4% paraformaldehyde. The brain, spinal cord and optic chiasm were removed, coronal slices were taken from the frontal, parietal and occipital levels of the cerebral hemispheres, from the cerebellum at the superior cerebellar peduncles and immediately caudal to the peduncles and from the spinal cord at the cervical, thoracic and lumbar levels. The tissue was dehydrated and embedded in paraffin. Ten micrometer sections were stained with hematoxylin and eosin for general cytoarchitecture, Luxol fast blue for myelin and by the Bodian technique (38) for axons and examined by light microscopy. For histological analysis of other organs, tissues were dissected, fixed in neutral buffered 10% formalin and embedded in paraffin. Five micrometer sections were prepared and stained with hematoxylin and eosin. Two to three sections of each tissue were examined by light microscopy by Dr Linda Johnson, a veterinary pathologist in the Albert Einstein College of Medicine Animal Institute. The following tissues were examined: calvarium, eye, salivary glands, pharynx, trachea, esophagus, thyroid, parathyroid, thymus, pituitary, heart, diaphragm, lung, spleen, liver, kidney, adrenal, stomach, pancreas, intestine, colon, cervical, thoracic and lumbar vertebrae, tibia, femur, sternum, uterus, prostate, testis, epididymis, seminal vesicle, coagulating and prepucial glands and urinary bladder.
Sperm counting
Epididymes were removed from three 9-week-old homozygous and wild-type males under sterile conditions and placed in a dish containing 1 ml DMEM medium (Gibco) (54) . The sperm were allowed to disperse into the medium for 2 h at room temperature and the number of spermatozoa was determined by counting in a hematocytometer.
RNA in situ hybridization
For RNA in situ hybridization a 570 bp probe (Gscl-3′) encompassing the third exon and a portion of the putative 3′-untranslated region was generated by PCR of genomic DNA using primers Gscl-3A (5′-cctcaggtctggttcaagaa-3′) and Gscl-X (5′-tggcatcagctcaaggct-3′). The PCR product was cloned into the PCR 2.1 plasmid from the TA Cloning Kit (Invitrogen) and then subcloned into pBluescript SK. Sense and antisense 33 P-labeled RNA probes were synthesized from linearized plasmid DNA, using either T3 or T7 RNA polymerase, respectively. Hybridization to paraffin-embedded embryo sections (Novagen) was performed according to a published protocol (55) . Hybridization was carried out at 60_C for 16 h in 50% deionized formamide, 0.3 M NaCl, 20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10 mM Denhardt's solution, 500 µg/ml yeast RNA, 0.1 M DTT with 5 × 10 6 d.p.m./ml 33 P-labeled RNA probe. After hybridization, sections were washed sequentially as follows: (i) 5× SSC, 10 mM DTT at 50_C for 30 min; (ii) 50% formamide, 2× SSC, 0.1 M DTT at 65_C for 20 min; (iii) twice in 0.1 M Tris-HCl, pH 7.5, 0.4 M NaCl, 50 mM EDTA for 10 min at 37_C; (iv) once in the same solution as in step (iii) but with 20 µg/ml RNase A at 37_C for 15 min. The slides were then dehydrated rapidly and processed for standard autoradiography using Kodak NTB-2 emulsion and exposed for 2-4 weeks at 4_C. After developing in Kodak D-19 developer and fixer, the sections were stained with hematoxylin and eosin and mounted. Observations and photography were carried out using both bright and dark fields on a Zeiss Axiophot microscope.
